LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was closed as part of the out-licensure of the drug to Boston Pharmaceuticals, which will continue further clinical development of LYS228/BOS-228

Conditions

Intra-abdominal Infections

Interventions

DRUG: LYS228
DRUG: Standard of care therapy

Sponsor

Novartis Pharmaceuticals